The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay at slowing the rate of retina lesion growth, the primary ...

An Enniskillen man has been given a lifetime ban from owning animals after one of his dogs was forced to have an eye surgically removed due to ...

While targeted radiation can be an effective treatment for brain tumours, subsequent potential necrosis of the treated areas can be hard to distinguish from the tumours on a standard MRI. A new ...

A 55-year-old white man with a medical history of well-controlled type 2 diabetes, rheumatoid arthritis and fibromyalgia ...

A patient with blink-triggered visual tilt shows a cortical lesion that initially mimicked a peripheral vestibular disorder.

Belite Bio announced positive topline results from the phase 3 DRAGON trial of Tinlarebant in patients with Stargardt disease ...

Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease December 1, 2025 8:00 ...

Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.

Belite Bio said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study, sending its shares up over 15% in premarket trading.

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt ...

In small case series, three patients had complete responses and two had partial responses ...